

Re-print: Maintenance (r) Alpha Lipoic Acid Reduces Sudden Cardiac Death in Geriatric Diabetes Mellitus II Patients



AUCTORES

Globalize your Research

Clinical Cardiology and Cardiovascular Interventions

Authored by

Gary L. Murray^{1*} and Joseph Colombo^{2,3}

¹Director of Clinical Research, The Heart and Vascular Institute,
Germantown, TN-USA.

²Parasympathetic & Sympathetic Nervous System Consultant, Franklin Cardiovascular
Associates, Sewell, New Jersey – USA

³Physio PS, Inc., Atlanta, Georgia – USA

Published Date

October 16, 2020

Published in the Journal of
Clinical Cardiology and Cardiovascular Interventions

Auctores Publishing, LLC

16192 Coastal Highway

Lewes, DE 19958,

USA

Re-print: Maintenance (r) Alpha Lipoic Acid Reduces Sudden Cardiac Death in Geriatric Diabetes Mellitus II Patients

Gary L Murray^{1*} and Joseph Colombo^{2,3}

¹Director of Clinical Research, The Heart and Vascular Institute, Germantown, USA

²Parasympathetic & Sympathetic Nervous System Consultant, Franklin Cardiovascular Associates, Sewell, New Jersey – USA

³Physio PS, Inc., Atlanta, Georgia – USA

*Corresponding author: Gary L Murray, The Heart and Vascular Institute, 7205 Wolf River Blvd, Germantown,

Received date: September 30, 2020; Accepted date: October 09, 2020; Published date: October 16, 2020

Citation: Gary L Murray and Joseph Colombo., (2020) Re-print: Maintenance (r) Alpha Lipoic Acid Reduces Sudden Cardiac Death in Geriatric Diabetes Mellitus II Patients. J, Clinical Cardiology and Cardiovascular Interventions, 3(9); Doi:10.31579/2641-0419/094

Copyright: © 2020 Gary L Murray, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Diabetes carries a two-fold risk of Sudden Cardiac Death (SCD). Diabetic Autonomic Neuropathy (DAN), often progressing to Cardiovascular Autonomic Neuropathy (CAN, critically low parasympathetic tone [P]), increases death 3.5-fold over 5 years, half sudden or non-renal. Oxidative stress is a major cause of DAN. Also, increased sympathetic tone (S), High Sympathovagal Balance [SB>2.5] increases SCD risk.

Objective: Dysautonomic diabetic II patients were treated with the antioxidant (r) Alpha Lipoic Acid (ALA), autonomic function followed, and Sudden Death (SD) compared to untreated patients.

Methods: 133 patients (mean age 66y/o) with DAN or CAN, diagnosed using the ANX 3.0 Autonomic Monitor (Physio PS, Inc., Atlanta, GA) was offered (r)-ALA: 83 agreed (Group 1), and 50 refused (Group 2). P and S were re-measured up to 3 times/yr (mean f/u 6.31 yrs); SCDs were recorded.

Results: A 43% Relative Risk Reduction (RRR) in SCD occurred with (r)-ALA (25% SCD Group 1 vs. 44% SCD Group 2, p=0.0076). Initial to final patients with high SB or CAN were 21.7%-12% (p=0.010), 10.8%-15.7% (p=0.045), Group 1 vs. 24%-22% (p=ns), 6%-12% (p=0.083), Group 2. Only Group 1 survivors increased mean resting P. The progressive increase in P's decline, increasing CAN risk, in the other patients correlated with mortality (p<0.001) and (r) ALA dose. Initially, Group 1 had insignificantly less high SB (p=0.449) and significantly more CAN (p=0.013) vs. Group 2. Finally, Group 1 had significantly less high SB (p=0.0967) vs. Group 2, also improving to insignificantly more CAN (p=0.261).

Conclusion: (r)-ALA was associated with a 43% RRR of SCD and favorable P and S changes.

Keywords: Alpha Lipoic Acid, Diabetic Autonomic Neuropathy, Sudden Death.

Abbreviations:

SCD-Sudden Cardiac Death,

DAN-Diabetic Autonomic Neuropathy,

CAN-Cardiovascular Autonomic Neuropathy,

P-Parasympathetic tone,

S-Sympathetic tone,

ALA-Alpha Lipoic Acid,

SD-Sudden Death,

NOH-Neurogenic Orthostatic Hypotension,

DMII-Type 2 Diabetics,

RA-Respiratory Activity,

HRV-Heart Rate Variability,

RFa-Respiratory Frequency area,

FRF-Fundamental Respiratory Frequency,

LFa-Low Frequency area,

ACS-Acute Coronary Syndromes,

VT/VF-Ventricular Tachycardia/Fibrillation,

CART-Cardiovascular Autonomic Reflex Test,

BMI-Body Mass Index, Bx-Baseline,

dBp- Diastolic Blood Pressure,

HL-Hyperlipidemia,

HR-Heart Rate,

LVEF-Left Ventricular Ejection Fraction,

PE-Parasympathetic Excess,

QTc-corrected QT,

SB-Sympathovagal Balance,

sBP-systolic BP,

SW-Sympathetic Withdrawal,

CKD-Chronic Kidney Disease.

Introduction

Diabetics have a two-fold increased risk of Sudden Cardiac Death (SCD), the most common cause of death in adult diabetics. Subgroup analyses have not explained this adequately [1]. Diabetic Autonomic Neuropathy (DAN) [2], carries a 53% 5yr. mortality, half of the deaths sudden [3]. DAN can progress to Cardiovascular Autonomic Neuropathy (CAN) in approximately 65% of patients with aging and diabetes duration [4]; CAN, critically low Parasympathetic tone (P), increased SCD in the Framingham Study [5]. Hyperglycemic- oxidative stress causes dysautonomia [6-8]. We hypothesized (r)-ALA, a natural, potent antioxidant, might reduce SCD in Type 2 Diabetics (DMII) with dysautonomias. We have shown previously (r)-ALA improves autonomics in Hypertension (HTN) [9] as well as Neurogenic Orthostatic Hypotension (NOH) [10].

Methods

In 2006, 133 consecutive DMII referrals for cardiovascular evaluation underwent P and S testing via ANX 3.0 Autonomic Monitoring (P&S Monitoring, Physio PS, Inc., Atlanta, GA). P&S were computed simultaneously and independently by concurrent, continuous time-frequency analysis of Respiratory Activity (RA) and Heart Rate Variability (HRV), as we detailed previously [11-17]. P&S srenormally; sitting LFa and RFa=0.5 to 10.0 bpm²; SB is age dependent=0.4 to 1.0 for geriatrics; stand LFa is ≥ 10% increase with respect to (wrt) sit; stand RFa is a decrease wrt sit. High SB is defined as >2.5, as established in our 483 patient study [18]. High SB and CAN define a high risk of mortality, Acute Coronary Syndromes (ACS), CHF, and Ventricular Tachycardia/Fibrillation (VT/VF) alone or as a composite endpoint [18].

In the 83 (r)-ALA patients (Group 1), P&S were recorded 2-3 mo. afterwards until maintenance dosage, then yearly. Non-(r)ALA patients (Group 2, refused (r)-ALA) were tested yearly. Exclusion criteria were (1) arrhythmia precluding HRV measurement, and (2) cancer within 5 yrs. The inclusion criterion was DM II with any abnormality of P or S. Informed consent was obtained for this open-label, un-blinded study. The cause of SD was determined from hospital records or death certificates. Out of hospital SCD was defined as pulse less SD of cardiac origin.

Group 1 patients were subcategorized: survivors, Group AA; non-survivors Group AD. Group 2 (Controls): survivors, Group NA; non-survivors, Group ND. All patients took aspirin. All patients had Cardiovascular Autonomic Reflex Test (CART) w/o isometric grip (grip has only 25% sensitivity for CAN) [19]. DAN was defined as any abnormality of S or P, or high SB. CAN was defined as P<0.10bpm², or 2 abnormalities of CARTs. Median follow-up was 5 yrs. Mean age was 66 y/o. There were 83 males, 50 females. Upon referral, rhythm

assessment (Holters ± event monitors) were performed if clinically indicated: Groups AA 60%, AD 57.1%, NA 60.7%, ND 31.8%.

The abbreviations are: Δ, change from initial to final; A1C, glucose form hemoglobin; (r) ALA ((r)Alpha-Lipoic Acid) (the r-isomer functional in humans); BMI (Body Mass Index); Bx (Baseline); CAN; DAN; dBP (Diastolic Blood Pressure); HL (Hyperlipidemia); HR (Heart Rate); Init (Initial); LFa ((Low Frequency area)=S)); LVEF (Left Ventricular Ejection Fraction); mg (milligrams); N (number); Nml (normal); ns (not significant); P (Parasympathetic tone); PE (Parasympathetic Excess); QTc (corrected QT); RFa ((Respiratory Frequency area)=P)); S (Sympathetic tone); SB (Sympathovagal Balance); sBP (systolic BP); SW (Sympathetic Withdrawal). Given the size of the cohort, statistical significance is p<0.100. Statistical significance was determined with either a two-tailed, student T-test or a Pearson correlation.

Results

25% of (r)-ALA patients experienced SCD vs. 44% non-(r)-ALA patients, a 43% Relative Risk Reduction (RRR, p=0.0076 [Figure 1]), altering the natural history of DAN [3].




Figure 1: Sudden Death Mortality risk of a Diabetic type 2 cohort from a south-central USA cardiology practice. (r)ALA (blue curve) reduced this cohort's relative risk ratio (RRR) by 43% (p=0.0076) as compared to controls (brown curve).

Demographics

Table 1 Survivor demographics Group AA had significantly more males and higher final A1C; their initial LVEF was insignificantly lower, factors not favoring survival [20-24]; tending to favor survival were insignificantly fewer with CAD (although all AA and NA patients were vascularized with normal stress tests), less Chronic Kidney Disease (CKD); and significantly more Angiotensin blocker therapy (ACEI or ARB, p<0.100) [20,25]. 11% more (r)-ALA patents required insulin. Control Group NA had significantly more females and lower final A1C; there were insignificantly higher initial LVEFs and insignificantly more patients on Empagliflozin, Liraglutid, and Metformin, tending to favor survival [26-29].

| | Group AA | | Group NA | | p |
|-------------------|-------------|------------|------------|------------|---------|
| N | 62 | | 28 | | |
| Male | 61% | | 39% | | p<0.100 |
| Age (mean yrs) | 67 | | 64 | | p>0.100 |
| Ethnicity | | | | | |
| Caucasian | 74% | | 73% | | ns |
| African Am | 23% | | 24% | | ns |
| Other | 3% | | 2% | | ns |
| 2° Dx | | | | | |
| HTN | 95.00% | | 86.00% | | ns |
| HL | 80.00% | | 82.00% | | ns |
| CAD | 24.00% | | 37.00% | | ns |
| CHF | 21.00% | | 20.00% | | ns |
| CKD | 25.00% | | 35.00% | | ns |
| Smoker | 5.00% | | 4.00% | | ns |
| AODM Rx | | | | | |
| Insulin | 25.00% | | 14.00% | | ns |
| Metformin | 14.50% | | 36.00% | | ns |
| Sulfonylurea | 9.70% | | 11.00% | | ns |
| Sitagliptin | 5.00% | | 7.00% | | ns |
| Empagliflozin | 1.50% | | 11.00% | | ns |
| Liraglutid | 5.00% | | 36.00% | | ns |
| Pioglitazone | 5.00% | | 0% | | ns |
| Anti-HTN Rx | | | | | |
| ACEI/ARB | 64% | | 41% | | p<0.100 |
| CCB | 39% | | 30% | | p<0.100 |
| BB | 36% | | 35% | | p>0.100 |
| Clonidine | 9% | | 3% | | p<0.100 |
| (r)ALA (mean mg) | 634 ± 458.5 | | 0 | | |
| | Initial | Final | Initial | Final | |
| BMI (mean kg/m2) | 31.6 ± 5.6 | 32.1 ± 6.6 | 32.7 ± 9.3 | 32.1 ± 6.5 | p>0.100 |
| A1c (meanmol/mol) | 6.22 ± 0.9 | 6.61 ± 0.6 | 6.7 ± 0.9 | 6.25 ± 0.5 | p=0.047 |
| LVEF (mean %) | 60 ± 11.1 | 60 ± 11.0 | 68 ± 11.8 | 60 ± 8.1 | p<0.100 |
| QTc (mean msec) | 373 ± 47.5 | 380 ± 50.3 | 370 ± 39.7 | 379 ± 44.5 | p>0.100 |

Note: 2° Dx=Secondary Diagnosis; ACEI=Angiotensin Converting Enzyme Inhibitor; ARB=Angiotensin Renin Blocker; BB=Beta-Blocker; CCB=Calcium Channel Blocker; HL=Hyperlipidemia; Rx=therapy.

Table 1: Survivor Patient Demographics.

Table 2 Non-Survivors. Group AD had significantly more males and higher A1C; there were insignificantly higher final BMI [24], lower LVEFs, more CHF, and less Metformin use, all tending unfavorably regarding survival. But 9% more took ACEI/ARBs (p<0.100). Control Group ND was 4 years older (p>0.100); QTc had no significance on SD, as SD increases when QTc is >450ms in males or >470ms in females [30]. Insignificantly more Group ND African Americans tends to favor SD [31]. CAD causes most adult SDs [24]. Although more SD patients had

CAD vs. survivors, CAD prevalence was insignificantly different in Groups AD, ND.

Group AA vs. Group ND: Improved Group AA survival occurred despite Group ND having a normal final BMI (p=0.067), less HTN (p=0.021), greater use of Empagliflozin (p<0.100), Metformin (p<0.100), lower final A1C (p=0.034), and fewer males (p<0.100), all favoring less SCD in Group ND. DMII attenuates gender differences in SD [22]. Group ND was 3 yrs. Older (p=0.067) with more CAD (p<0.100); all were revascularized (normal myocardial perfusion stress tests). Fewer in Group AA took insulin (p<0.100). Initially, Group AA had 18.4% VT (1 sustained) vs. 14.3% non-sustained in Group ND, p=0.3559.

| | Group AD | | Group ND | | p |
|--------------------|-------------|-------------|-------------|-------------|---------|
| N | 21 | | 22 | | |
| Male | 91% | | 41% | | p<0.100 |
| Age (mean yrs.) | 66 ± 12.3 | | 70 ± 11.5 | | p>0.100 |
| Ethnicity | | | | | |
| Caucasian | 81% | | 73% | | ns |
| African Am | 11% | | 28% | | ns |
| 2° Dx | | | | | |
| HTN | 68.00% | | 59.00% | | ns |
| HL | 96.00% | | 86.00% | | ns |
| CAD | 67.00% | | 73.00% | | ns |
| CHF | 38.00% | | 23.00% | | ns |
| CKD | 27.00% | | 30.00% | | ns |
| Smoker | 5.00% | | 4.50% | | ns |
| AODM Rx | | | | | |
| Insulin | 42.00% | | 45.00% | | ns |
| Metformin | 10.00% | | 45.00% | | ns |
| Sulfonylurea | 19.00% | | 13.60% | | ns |
| Sitagliptin | 11.00% | | 9.00% | | ns |
| Empagliflozin | 5.00% | | 13.60% | | ns |
| Pioglitazone | 5.00% | | 0% | | ns |
| Anti-HTN Rx | | | | | |
| ACEI/ARB | 73% | | 64% | | p<0.100 |
| CCB | 27% | | 11% | | p<0.100 |
| BB | 50% | | 64% | | p>0.100 |
| HCTZ | 25% | | 25% | | p>0.100 |
| (r)ALA (mean mg) | 548 ± 306.8 | | 0 | | |
| | Initial | Final | Initial | Final | |
| BMI (mean kg/m2) | 30.7 ± 10.3 | 32.4 ± 11.2 | 30.3 ± 10.2 | 28.8 ± 11.0 | p<0.100 |
| A1C (meanmmol/mol) | 7.74 ± 1.0 | 6.3 ± 0.6 | 6.59 ± 0.9 | 6 ± 0.6 | p<0.100 |
| LVEF (mean %) | 57 ± 10.5 | 48 ± 9.1 | 59 ± 10.4 | 61 ± 8.4 | p<0.100 |
| QTc (mean msec) | 390 ± 51.2 | 430 ± 54.6 | 386 ± 41 | 454 ± 43.3 | p>0.100 |

Note: HCTZ, hydrochlorothiazide. See Table 1 or Methods for other abbreviations.

Table 2: Non-Survivor Patient Demographics (Sudden Death Patients).

Group NA vs. Group AD: NA patients were 2 yrs. Younger (p=0.081); more hypertensive (p=0.086); had greater use of Empagliflozin (p<0.100), Metformin (p<0.100), Liruglutid (p<0.100), higher final

LVEFs (60% vs. 48%, p<0.100), fewer males (p<0.100), and less CAD (p<0.100; revascularized with normal stress tests), mostly favoring survival. Fewer in Group NA took insulin (p<0.100). Initially, Group NA had 0% non-sustained VT vs. 16.7% in Group AD, p=0.1661.

Autonomic Measures: Table 3: Survivors and SCD patients initial to final autonomic Measures. Mean Bx LFa, decreased in survivors (p=0.045), increasing in SCD (p=0.039). Bx RFa, increased in 55/90 patients (60%), by a mean 12.5% in survivors and severely decreased in 29/43 (67%) non-survivors, mean -59.5%, (p<0.0001). SB increased 17.6% in survivors, but had a greater increase in SCD to >2.5: +29.5% (p=0.064).

Non-Survivors demonstrated a more abnormal final alpha-S-response standing, SW (-24.4% vs. -13.8% [p=0.066]), indicating greater Bar receptor Reflex dysfunction, which increases SCD risk. PE upon standing developed more significantly in survivors (+65%) vs. SCD (+29%) because initial to final standing RFa increased in survivors vs. decreasing in SCD (p=0.022). In parallel, SCD patients experienced a dramatic 59.5% decrease in resting P in addition to SW. All P- and S- final values were lower in SCD, the lowest being resting P. Since HRV=S+P, HRV was lower in SCD (p<0.0001) mainly due to lower P.

Survivors

Group-AA, Survivors with (r)-ALA: (Table 4) A1C increased (increasing oxidative stress, p=0.047), inversely proportional to (r)- ALA dosage (p=0.071); but resting RFa increased proportionally (p=0.014). Average resting Bx LFa increased (p=0.095) as did resting Bx RFa (p=0.070). HRV increased. The mean initial standing response was SW. At final testing, 4 patients' SW were relieved (p=0.097);

Consequently, BRS improved. One more patient demonstrated PE (p=0.098) (standing RFa increased) proportional to (r)-ALA dosage.

| N | Survivors | | | | Sudden Cardiac Death | | | |
|------------------------------|-------------|-------------|-------|---------|----------------------|-------------|-------|---------|
| | 90 | | | | 43 | | | |
| | Initial | Final | Δ% | p | Initial | Final | Δ% | p |
| Sitting (Rest) | | | | | | | | |
| LFa (bmp²) | 1.25 ± 2.19 | 1.1 ± 1.55 | -12 | p=0.045 | 0.89 ± 1.60 | 0.93 ± 1.09 | 4.5 | p=0.039 |
| RFa (bmp²) | 1.2 ± 2.33 | 1.35 ± 1.50 | 12.5 | p=0.079 | 1.11 ± 1.93 | 0.45 ± 0.47 | -59.5 | p=0.054 |
| SB1.23 ± 1.50 | 1.76 ± 1.47 | 2.07 ± 1.49 | 17.6 | p=0.064 | 2.03 ± 1.92 | 2.63 ± 2.60 | 29.5 | p=0.064 |
| Standing | | | | | | | | |
| LFa (bmp²) | 1.16 ± 2.05 | 1 ± 1.22 | -13.8 | p=0.056 | 0.9 ± 1.28 | 0.68 ± 0.91 | -24.4 | p=0.005 |
| RFa (bmp²) | 0.97 ± 1.70 | 1.75 ± 1.95 | 80.4 | p=0.051 | 0.82 ± 1.21 | 0.58 ± 0.66 | -29.3 | p<0.001 |

Note: HCTZ, hydrochlorothiazide; Standing represents positive head-up posture, equivalent to head-up tilt. See Table 1 or Methods for other abbreviations.

Table 3: Comparison between Survivors and Sudden Cardiac Death patients, Mean P&S Measures. See Methods for parameters' normal ranges.

| DMII(r)ALA Survivors (Group AA) | | | | N=62 | |
|---------------------------------|---------------|---------------|----------------|-------|-------|
| Age | 66.5 | Range: | 48to 89 | | |
| (r)ALA (mg) | 637.1 ± 458.5 | | | | |
| Population | Initial | Final | Δ | p:Δ | p:ALA |
| SB>2.5 | 13 | 4 | -9 | ns | ns |
| CAN | 8 | 5 | -3 | 0.08 | 0.004 |
| BMI | 32.2 ± 5.6 | 32.1 ± 6.6 | -0.1 | ns | ns |
| LVEF | 63.2 ± 11.1 | 60.7 ± 11.0 | -2.5 | ns | ns |
| QTc | 375.2 ± 47.5 | 380.7 ± 50.3 | 2.5 | ns | ns |
| A1C | 6.2 ± 0.9 | 6.6 ± 0.6 | 0.3 | 0.047 | 0.071 |
| BxLFa | 1.03 ± 2.0 | 1.08 ± 1.7 | 0.06 | 0.095 | ns |
| BxRFa | 0.8 ± 1.3 | 1.09 ± 0.6 | 0.29 | 0.07 | 0.014 |
| Bx SB | 1.8 ± 1.4 | 2.1 ± 1.8 | 0.31 | ns | ns |
| Bx HR | 70.2 ± 13.2 | 68.9 ± 12.0 | -1.3 | ns | 0.089 |
| BxsBP | 134.2 ± 17.7 | 135.8 ± 17.9 | 1.5 | ns | ns |
| BxdBP | 73.8 ± 12.2 | 68.5 ± 10.1 | 5.3 | 0.019 | 0.009 |
| Stand LFa | 1.01 ± 1.55 | 0.9 ± 1.16 | -0.11 | 0.073 | ns |
| Stand RFa | 0.58 ± 1.85 | 0.91 ± 0.77 | 0.34 | 0.053 | ns |
| SW | 37 | 33 | -4 | ns | 0.097 |
| PE | 26 | 27 | 1 | ns | 0.098 |
| Individuals | | N= | No Δ | (+) | (-) |
| ΔSB | | | 16 | 6 | 40 |
| ΔHR | | | 4 | 53 | 5 |
| ΔsBP | | | 10 | 15 | 37 |
| ΔdBp | | | 14 | 43 | 5 |
| ΔBP | | | 21 | 37 | 4 |
| SW | | | 24 | 21 | 17 |
| PE | | | 33 | 14 | 15 |

Note: (+), improved; (-), declined; Δ, change? Demonstrated; ns, not significant (p>0.100); See Table 1 or Methods for other abbreviations.

Table 4: Mean P&S measures for DM II Survivors on (r)ALA (GroupAA).

Group-NA, Survivors without (r)-ALA: (Table 5) Similar to Group-AA, the average initial P&S levels are normal, and given their age, SB is high (but lower than Group AA and not >2.5). Contrary to Group AA, final BxLFa decreased (p=0.075), as did BxRFa (and HRV). SB increased (p=0.088). Standing, Group-NA initially demonstrated normal P- and slightly low S-responses. Individually, 57.1% demonstrated SW. Of these, 81.3% demonstrated PE. At final testing, 2 patients' SW were relieved; 5 relieved PE, different from the Group AA patients (p<0.027).

| DMII No (r)ALA Survivors (Group NA) | | | | N=28 | |
|-------------------------------------|--------------|---------------|-----------------|-------|----|
| Age | 63.2 | Range: | 45 to 88 | | |
| (r)ALA (mg) | 0 | | | | |
| Population | Initial | Final | Δ | p: Δ | |
| SB>2.5 | 5 | 6 | 1 | ns | |
| CAN | 0 | 1 | 1 | ns | |
| BMI | 34.2 ± 9.3 | 32.1 ± 6.5 | -2.1 | ns | |
| LVEF | 68 ± 11.0 | 62.8 ± 8.1 | -5.2 | ns | |
| QTc | 372.3 ± 39.7 | 379.2 ± 44.5 | 6.9 | ns | |
| A1C | 6.7 ± 0.9 | 6.3 ± 0.5 | -0.4 | ns | |
| BxLFa | 1.74 ± 2.6 | 1.14 ± 1.1 | -0.6 | 0.075 | |
| BxRFa | 2.1 ± 3.6 | 1.94 ± 3.7 | -0.16 | ns | |
| Bx SB | 1.67 ± 1.6 | 1.73 ± 1.5 | 0.06 | 0.088 | |
| BxsBP | 135.3 ± 21.1 | 138.1 ± 20.8 | 2.8 | ns | |
| BxdBP | 72.8 ± 12.4 | 70.8 ± 8.9 | -2 | 0.049 | |
| Stand LFa | 1.86 ± 2.82 | 1.16 ± 1.35 | -0.7 | 0.092 | |
| Stand RFa | 1.66 ± 2.71 | 1.06 ± 2.19 | -0.6 | ns | |
| SW | 16 | 14 | -2 | ns | |
| PE | 13 | 8 | -5 | ns | |
| Individuals | N= | No Δ | (+) | (-) | |
| ΔSB | | | 9 | 6 | 13 |
| ΔsBP | | | 5 | 10 | 13 |

| | | | | |
|------|--|----|----|---|
| AdBP | | 4 | 22 | 2 |
| ΔBP | | 8 | 19 | 1 |
| SW | | 14 | 8 | 6 |
| PE | | 19 | 7 | 2 |

Note: (+), improved; (-), declined; Δ, change demonstrated; ns, not significant (p>0.100); See Table 1 or Methods for other abbreviations.

Table 5: Mean P&S measures for DM II Survivors not on (r)ALA (Group NA), the control group.

Survivors' Mortality Risk: 13% Group AA patients demonstrated CAN initially, improving to 8.1%, proportional to (r)-ALA dose (p=0.004). Group AA was the only Group that increased resting BxRFa, (Table 4). Group-AA's final RFa increased 36.2%, correlating with the dose of (r)-ALA (p=0.014). Group AA's increase in resting BxLFa (Table 4) was mitigated by the increase in resting BxRFa, so the SB change was insignificant. Group NA had no CAN initially; increasing to 3.6%. This group's average resting BxLFa decreased (34.5%); BxRFa fell 7.6%. SB (the average of 4 sec. ratios, not the ratio of these reported averages) significantly increased 3.6% (p=0.088), increasing MACE risk. In Tables 4 and 5, Group AA's BxLFa and BxRFa were initially lower than Group NA's (p<0.100), indicating lower HRV. Group AA increased both, decreasing mortality risk (Table 4). Group NA decreased both BxLFa (Table 5) (p=0.075) and BxRFa (p=ns), indicating an accelerated progression towards increased mortality risk (decreased HRV).

Non-Survivors

Group AD, Non-Survivors with (r)-ALA: (Table 6) Initial P&S levels are below normal and lowest of all Groups (lowest HRV). Given their age, SB is high (but not >2.5). Final LFa increased (p=0.047); RFa decreased (p=0.098); and SB increased to 2.72. Resting P protects against VT/VF and silent ischemia [21,32-36]; seven progressed to CAN (p=0.080), not surprising since initial BxRFa was so severely depressed. Group AD was beyond help. Standing, 57% of Group AD initially demonstrated PE; 33% ended with PE (p=0.061) and 57% ended with SW (p=0.037) indicative of BRS dysfunction (increases SCD). Finally, Group AD's, average stand LFa was SW. These Sympathetic results are significantly similar to Group AA (p=0.061). However, the P-responses, are different (p=0.185).

Group ND, Non-Survivors without (r)-ALA: (Table 7) Initial resting BxLFa, resting BxRFa, were normal; SB high for age (but not >2.5 Final BxLFa decreased, p=0.100; BxRFa severely decreased, p=0.020. Two more patients (67%) developed CAN (p=0.020) in spite of initially good BxRFa. Group ND's initial standing P was normal, but S showed SW. Final average S-stand remained SW; P barely normalized. The P-responses as compared with the Group-AA are different (p=0.106).

| | | | | | |
|---|---------------|---------------|----------|-------|-------------|
| DMII (r)ALA Non-Survivors (Group AD) | | | | | N=21 |
| Age | 65.7 | Range: | 47 to 89 | | |
| (r)ALA (mg) | 528.6 ± 306.8 | | | | |
| Population | Initial | Final | Δ | p:Δ | p:ALA |
| SB>2.5 | 5 | 6 | 1 | ns | ns |
| CAN | 1 | 8 | 7 | 0.08 | 0.014 |
| BMI | 32.1 ± 10.3 | 31.4 ± 11.2 | -0.8 | ns | ns |
| BxLFa | 0.44 ± 0.9 | 0.92 ± 1.1 | 0.48 | 0.047 | ns |
| BxRFa | 0.38 ± 0.4 | 0.34 ± 0.4 | -0.04 | 0.098 | 0.033 |
| Bx SB | 2.13 ± 2.3 | 2.72 ± 2.4 | 0.59 | ns | 0.028 |
| BxsBP | 133.9 ± 22.7 | 139 ± 24.4 | 5.1 | ns | ns |
| BxdBP | 71.1 ± 14.8 | 68.2 ± 7.9 | -2.9 | ns | ns |
| Stand LFa | 0.71 ± 1.2 | 0.68 ± 0.9 | -0.03 | ns | 0.092 |
| Stand RFa | 0.58 ± 1.1 | 0.24 ± 0.2 | -0.34 | ns | ns |
| SW | 16 | 12 | -4 | 0.037 | 0.06 |

| | | | | | |
|--------------------|----|----|------|-------|-----|
| PE | 12 | 7 | -5 | 0.061 | ns |
| Individuals | | N= | No Δ | (+) | (-) |
| ΔSB | | | 4 | 6 | 11 |
| ΔsBP | | | 6 | 2 | 13 |
| ΔdBP | | | 7 | 11 | 3 |
| ΔBP | | | 11 | 9 | 1 |
| SW | | | 11 | 3 | 7 |
| PE | | | 10 | 3 | 8 |

Note: (+), improved; (-), declined; Δ, change? Demonstrated; ns, not significant (p>0.100); See Table 1or Methods for other abbreviations.

Table 6: Mean P&S measures for DM II Non-Survivors on (r)ALA (Group AD).

| | | | | |
|--|--------------|---------------|----------|-------------|
| DMII No (r)ALA Non-Survivors (Group ND) | | | | N=22 |
| Age | 70.2 | Range: | 47 to 90 | |
| (r)ALA (mg) | 0 | | | |
| Population | Initial | Final | Δ | p:Δ |
| SB>2.5 | 7 | 5 | -2 | ns |
| CAN | 3 | 5 | 2 | 0.02 |
| BMI | 30.6 ± 7.5 | 28.8 ± 7.3 | -1.8 | ns |
| BxLFa | 1.4 ± 2.0 | 0.86 ± 1.1 | -0.54 | 0.1 |
| BxRFa | 1.69 ± 2.5 | 0.55 ± 0.5 | -1.14 | 0.02 |
| Bx SB | 1.93 ± 1.5 | 2.55 ± 2.8 | 0.62 | ns |
| BxsBP | 136.6 ± 15.7 | 135.8 ± 19.4 | -0.9 | 0.059 |
| BxdBP | 71.9 ± 19.2 | 66.8 ± 11.0 | -5.1 | 0.034 |
| Stand LFa | 1.05 ± 1.3 | 0.69 ± 0.9 | -0.36 | ns |
| Stand RFa | 1.05 ± 1.3 | 0.54 ± 0.9 | -0.51 | ns |
| SW | 13 | 15 | 2 | ns |
| PE | 10 | 10 | 0 | ns |
| Individuals | N= | No Δ | (+) | (-) |
| ΔSB | | 7 | 3 | 12 |
| ΔsBP | | 17 | 5 | 0 |
| ΔdBP | | 1 | 16 | 5 |
| ΔBP | | 11 | 9 | 2 |
| SW | | 10 | 5 | 7 |
| PE | | 16 | 3 | 3 |

Note: (+), improved; (-), declined; Δ, change demonstrated; ns, not significant (p > 0.100); See Table 1or Methods for other abbreviations.

Table 7: Mean P&S measures for DM II Non-Survivors not on (r)ALA (Group ND).

Mortality Risk: Resting BxRFa decreased in both Groups (Tables 6&7): 10.5%, Group AD and 67.5%, Group ND (p=0.033); a higher risk of developing CAN. Final SB was >2.5 in both, which we have shown increases MACE 700% [18]. SB greater than 2.5 with CAN is particularly deadly in both Groups, and final average standing response was SW (impaired BRS), increasing SCD as well. BxLFa increased in Group AD (Table 6) by 109.1% vs. decreasing 38.6% in Group ND (Table 7, p=0.100), causing increased SB in Group AD.

In Group ND, despite the decrease in S, the severe decrease in resting BxRFa increased SB anyway. Two more patients had CAN. Non-survivors' (r)ALA preserved their severely lowest P and S (LOWEST HRV) even in death. Group ND's final BxLFa and BxRFa fell severely to the 2nd lowest among all Groups. CAN and high SB were most frequent in Groups AD and ND.

Traditional Standards Comparison: Comparing the gold standard of CARTs, without isometric hand-grip, to any abnormality of P&S Monitoring for diagnosing DAN or CAN, CARTs' sensitivity was 48.2%

of Group 1 and 30.0% of Group 2 patients; an overall unsatisfactory sensitivity of 41.4%.

Discussion

Administration of (r)ALA resulted in a 43% RRR of SCD, rather than the demographics that may have favored survival in Controls. Rapid separation of the SCD curves (Figure 1) strongly implies treatment effect. Lower initial HRV, Group 1 vs. Group 2, $p < 0.0001$, predicted SCD: AA 1.83 vs. AD 0.82, $p = 0.0171$; NA 4.14 vs. ND 3.09,

$p = 0.0051$. More initial CAN ((r)ALA 10.8% vs. Controls 6%, $p = 0.0013$) and initial BRS dysfunction ((r)ALA 63.9% vs. Controls 58%, $p = 0.0044$) predicted SCD better than recorded VT. (r)ALA preserved P and S vs. Controls. Those with the lowest P&S (HRV) died. Reduced HRV is a common thread in SCD Only Group AA demonstrated an increase in final, resting P (and HRV); P reduces VT/VF and silent ischemia [21,32-36], increasing 36.2% vs. a 7.6% decrease for Group NA, a 10.5% decrease for Group AD, and a 67.5% decrease for Group ND.

The progressive increase in the decline of resting P indicated mortality, from the lowest decline in resting P in Group NA, to the next greater decline in Group AD, to those with the greatest decline, Group ND ($p < 0.001$). Changes in P were proportional to (r)ALA dose. These trends are not found in the other physiologic measures: BMI, LVEF, and QTc; and only different between the survivors' AICs (Group AA vs. Group NA, $p = 0.034$). Since SW and PE can cause both NOH and systemic HTN [9,10]. DMII patients not on (r)ALA might experience orthostasis, or labile HTN. HTN could be secondary (neurogenic), and is over twice as well controlled treating the primary SW \pm PE [9] than treating the BP per se. (r)ALA preserved P and S, especially P, in survivors and non-survivors. (r)ALA is a natural, powerful thiol antioxidant. (r)ALA restores and recycles vitamins A,C,E and glutathione [9,10,34].

It improves hyperglycemia, endothelial dysfunction, nitric oxide levels (protective against VT/VF, silent ischemia [37-40]), reduces nuclear kappa B, and is essential for certain mitochondrial oxidative enzymes. (r)ALA prevents diabetic-induced reduction of the afferent limb function of the baroreceptor reflex (BR) [41], reducing MACE. SW, found in 50% to 74% of patients, failed to correct in 88% of Group NA and all SCD patients. SW disappeared substantially only in Group AA, 59.7% reduced to 53.2%, $p = 0.097$, decreasing SCD risk. The other most common, and most important, P&S finding was low resting P in 56% to 81% of patients, improving only in Group AA (initial 56%, final 9%; $p = 0.070$), vs. Group NA (initial 29%, final 43%; $p = 0.098$), and worsening most severely in Group ND patients, a 67% reduction in RFA vs. 10.5% reduction in Group AD ($p = 0.020$).

CAN decreased 37.5% in Group AA vs. an increase of 67% in Group ND. 29% of Group AD had high SB vs. 50% in Group ND ($p = 0.037$). More CAN in Group 2 increased mortality; high SB increased mortality risk in Group 1. Group 1's autonomic profiles generally stabilized or improved (HRV); Group 2's deteriorated, especially a 59.5% decrease in resting P, reducing Group 2's ability to combat VT/VF, silent ischemia, and life stresses. Standard deviations decreased over time, with the most decreases correlating with the (r)ALA dosage. The pleiotropic effects of (r)ALA likely contributed to

SCD reduction. Increased nitric oxide improves P&S, endothelial dysfunction, protects against VT/VF and silent ischemia [37-40]. Decreased nitric oxide levels prolong QTc [37]. Improved mitochondrial function should reduce SCD also [42]. Asymptomatic SW (BR dysfunction) was the most common presentation of DAN. Approximately

90% of patients had HTN, presumed to be essential (primary), not possibly secondary to DAN. Ultimately, CAN with, or without, dangerously high SB can develop while under our care. How simple it is to diagnose and treat dysautonomia early; how tragic it may be not to.

References

1. Aune D, Schlesinger S, Norat T and Riboli E. Diabetes mellitus and the risk of sudden cardiac death: a systematic review and meta-analysis of prospective studies (2018) *Nutr Metab Cardiovasc Dis* 28:543-556. <https://doi.org/10.1016/j.numecd.2018.02.011>
2. Vinik A, Mitchell B, Maser R and Freeman R. Diabetic Autonomic Neuropathy (2003) *Diabetes Care* 26: 1553-1579. <https://doi.org/10.2337/diacare.26.5.1553>
3. Ewing D, Campbell I and Clarke B. The natural history of diabetic autonomic neuropathy (1980) *Q J Med Winter* 49: 95-108.
4. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management (2011) *Diabetes Metab Res Rev* 27: 639-653. <https://doi.org/10.1002/dmrr.1239>
5. Tsuji H, Larson M, Venditti F, Manders E, Evans J, et al. Impact of reduced heart rate variability on risk of cardiac events: The Framingham Heart Study (1996) *Circulation* 94: 2850-2855. <https://doi.org/10.1161/01.cir.94.11.2850>
6. Rolo A and Palmeira C. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress (2006) *Toxicol Appl Pharmacol* 212: 167-178. <https://doi.org/10.1016/j.taap.2006.01.003>
7. Hussain N and Adrian T. Diabetic Neuropathy: Update on pathophysiological mechanism and the possible involvement of glutamate pathways (2017) *Curr Diabetes Rev* 13: 488-497. <https://doi.org/10.2174/1573399812666160624122605>
8. Yorek M. The role of oxidative stress in diabetic vascular and neural disease (2003) *Free Radic Res* 37: 471-480.
9. Murray G and Colombo J. The feasibility of blood pressure control with autonomic-assisted hypertension therapy versus JNC8 therapy (2020) *Clinical Cardiol Cardiovascular Med* 4:1-5. <https://doi.org/10.31579/2641-0419/055>
10. Murray G and Colombo J. (r)Alpha lipoic acid is a safe, effective pharmacologic therapy of chronic orthostatic hypotension associated with low sympathetic tone (2019) *Int J Angiol* 28: 188-193. <https://doi.org/10.31579/2641-0419/055>
11. Aysin B, Colombo J and Aysin E. Comparison of HRV analysis methods during orthostatic challenge: HRV with respiration or without? 2007 29th Int Conf IEEE EMBS Lyon, France. <https://doi.org/10.1109/iembs.2007.4353474>
12. Akselrod S, Gordon D, Ubel F, Shannon D, Berger A, et al. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control (1981) *Sci* 213: 220-222. <https://doi.org/10.1126/science.6166045>
13. Akselrod S, Gordon D, Madwed J, Snidman N, Shannon D, et al. Hemodynamic regulation: Investigation by spectral analysis (1985) *Am J Physiol* 249: H867-H873. <https://doi.org/10.1126/science.6166045>
14. Akselrod S, Eliash S, Oz O and Cohen S. Hemodynamic regulation in SHR: investigation by spectral analysis (1987) *Am J Physiol* 253: H176-H183. <https://doi.org/10.1152/ajpheart.1987.253.1.h176>
15. Akselrod S. Spectral analysis of fluctuations in cardiovascular parameters: a quantitative tool for the investigation of

- autonomic control. *Trends Pharmacol Sci* 9: 6-9. [https://doi.org/10.1016/0165-6147\(88\)90230-1](https://doi.org/10.1016/0165-6147(88)90230-1)
16. Colombo J, Arora R, DePace N and Vinik A. *Clinical Autonomic Dysfunction: Measurement, Indications, Therapies, and Outcomes* (2014) Springer Science, USA.
 17. Bloomfield DM, Kaufman ES, Bigger JT Jr, Fleiss J, Rolnitzky L, et al. Passive head-up tilt and actively standing up produce similar overall changes in autonomic balance (1997) *Am Heart J* 134: 316-320. [https://doi.org/10.1016/s0002-8703\(97\)70140-6](https://doi.org/10.1016/s0002-8703(97)70140-6)
 18. Murray G and Colombo J. Routine measurements of cardiac parasympathetic and sympathetic nervous systems assists in primary and secondary risk stratification and management of cardiovascular clinic patients (2019) *Clinical Cardiovascular Med* 3: 27-33. <https://doi.org/10.33805/2639.6807.122>
 19. Korei A, Kempler M, Istenes I, Vagi D, Putz Z, et al. Why not use the handgrip test in the assessment of cardiovascular autonomic neuropathy among patients with diabetes mellitus? (2017) *Curr Vasc Pharmacol* 15: 66-73. <https://doi.org/10.2174/1570161114666160822154351>
 20. Kannel W and Schatzkin A. Sudden death: lessons from subsets in population studies (1985) *J Am CollCardiol* 5: 141B-149B. [https://doi.org/10.1016/s0735-1097\(85\)80545-3](https://doi.org/10.1016/s0735-1097(85)80545-3)
 21. Umetani K, Singer DH, McCraty R, and Atkinson M. Twenty-four hour time domain heart rate variability and heart rate: Relations to age and gender over nine decades (1998) *JACC* 31: 593- 601. [https://doi.org/10.1016/s0735-1097\(97\)00554-8](https://doi.org/10.1016/s0735-1097(97)00554-8)
 22. Kucharska-Newton A, Couper D, Pankow J, Prineas R, Rea T, et al. Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities Study (2010) *Acta Diabetol* 47: 161-168.
 23. Patel R, Moorthy M, Chiuve S, Pradhan A, Cook N, et al. Hemoglobin A1c levels and risk of sudden cardiac death: A nested case-control study (2017) *Heart Rhythm* 14: 72-78. <https://doi.org/10.1016/j.hrthm.2016.08.044>
 24. Kuriachan V, Sumner G and Mitchell L. Sudden cardiac death (2015) *Curr Probl Cardiol* 40: 133-200.
 25. Aljaroudi W, Refaat M, HabibR Al-Shaar L, Singh M, Gutmann R, et.al. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study (2015) *Am J Cardiol* 1: 924-931. <https://doi.org/10.3410/f.725363020.793512706>
 26. Suttar N, McLaren J, Kristensen S, Priess D and McMurray J. SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? *Diabetologia* (2016) 59: 1333-13339. <https://doi.org/10.1007/s00125-016-3956-x>
 27. Roussel R, Travert F, Pasquet B, Wilson P, Smith S, et al. Metformin use and mortality among patients with diabetes and atherothrombosis (2010) *Arch Intern Med* 170: 1892-1899. <https://doi.org/10.1001/archinternmed.2010.409>
 28. Simard P, Presse N, Rov L, Dorais M, White-Guay B, et al. Association between metformin adherence and all-cause mortality among new users of metformin: A nested case-control study (2018) *Ann Pharmacother* 52: 305-313. <https://doi.org/10.1177/1060028017743517>
 29. Costa E, Goncalves A, Areas M and Morgabel R. Effects of metformin on QT and QTc interval dispersion of diabetic rats (2008) *Arg Bras Cardiol* 90: 232-238.
 30. Straus S, Kors J, De Bruin M, van der Hooft C, Hofman A, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults (2006) *J Am Coll Cardiol* 47: 362-367. <https://doi.org/10.1016/j.jacc.2005.08.067>
 31. Reinier K, Rusinaru C and Chugh S. Race, ethnicity, and the risk of sudden death (2019) *Trends Cardiovasc Med* 29: 120-126.
 32. Curtis BM and O'Keefe JH. Autonomic tone as a cardiovascular risk factor: The dangers of chronic fight or flight (2002) *Mayo Clin Proc* 77: 45-54. <https://doi.org/10.4065/77.1.45>
 33. Kalla M, Herring N and Patterson D. Cardiac sympatho-vagal balance and ventricular arrhythmia (2016) *Auton Neurosci* 199: 29-37. <https://dx.doi.org/10.1016%2Fj.autneu.2016.08.016>
 34. Gomes M and Negrato C. Alpha lipoic acid as a pleotropic compound with potential therapeutic use in diabetes and other chronic diseases (2014) *Diabetol Metab Syndr* 6: 80-89. <https://doi.org/10.1186/1758-5996-6-80>
 35. Maser R and Lenhard M. An overview of the effect of weight loss on cardiovascular autonomic function (2007) *Curr Diabetes Rev* 3: 204-211.
 36. Kurpesa M, Trzos E, Drozd J, Bednarkiewicz Z and Krzeminska- Pakuta M. Myocardial ischemia and autonomic activity in dippers and non-dippers with coronary artery disease: Assessment of normotensive and hypertensive patients (2002) *Int J Cardiol* 83: 133-142. [https://doi.org/10.1016/s0167-5273\(02\)00031-1](https://doi.org/10.1016/s0167-5273(02)00031-1)
 37. Eijgelsheim M, Aamoudas A, Rivadeneira F, Kors J, Witteman J, et al. Identification of a common variant at the NOS1AP locus strongly associated to QT-interval prolongation (2009) *Human Mol Genet* 18: 347-357. <https://doi.org/10.1093/hmg/ddn341>
 38. Rakhit A, Maguire C, Wakimoto H, Gehrman J, Li G, et al. In vivo electrophysiologic studies in endothelial nitric oxide synthase (eNOS)-deficient mice (2001) *J Cardiovasc Electrophysiol* 12: 1295-1301. <https://doi.org/10.1046/j.1540-8167.2001.01295.x>
 39. Horinaka S, Kobayashi N, Yabe A, Asakawa H, Yagi H, et al. Nicorandil protects against lethal ventricular arrhythmias and up-regulates endothelial nitric acid synthase expression and sulfonylurea receptor 2 mRNA in conscious rats with acute myocardial infarction (2004) *Cardiovasc Drugs Ther* 18: 13-22. <https://doi.org/10.1023/b:card.0000025751.82774.a9>
 40. Hino V, Ohkubo T, Katsubi Y and Ogawa S. Changes in endothelium-derived vascular regulatory factors during dobutamine-stress-induced silent myocardial ischemia in patients with Kawasaki disease (1999) *Jpn Circ J* 63: 503-508. <https://doi.org/10.1253/jcj.63.503>
 41. Gouty S, Regalia J, Cai F and Helke C. Alpha-lipoic acid treatment prevents the diabetes-induced attenuation of the afferent limb of the baroreceptor reflex in rats (2003) *Auton Neurosci* 108: 32-44. <https://doi.org/10.1016/j.autneu.2003.08.004>
 42. DePace NL and Colombo J. *Autonomic and Mitochondrial Dysfunction in Clinical Diseases: Diagnostic, Prevention, and Therapy* (2019) Springer Science + Business Media, United States.